Quest, Ciphergen deal will build intellectual capital
This article was originally published in Clinica
US firms Ciphergen Biosystems and Quest Diagnostics have formed a strategic alliance to develop and commercialise assay tests based on Ciphergen's proprietary SELDI ProteinChip technology. Under the terms of the agreement, Quest has also claimed a 17.4% stake in Ciphergen, with an option to extend.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.